Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV13 in healthy infants and children
NCT06617715Phase 3Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sinovac PCV13 in pneumococcal infection (2 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Proportion of pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/mL and Pneumococcal serotype-specific IgG antibody geometric mean concentration. Started Oct 2024; status: recruiting.
02
Drugs
Sinovac PCV13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06617715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617715.